Oct 2026· ACS Medicinal Chemistry Letters· 0 citations· 13 references
TL;DR
The discovery of a pyrazolopyrimidine series as potent and orally bioavailable MRGPRX2 antagonists and establish the pyrazolopyrimidine chemotype as a promising scaffold for inhibition of MRGPRX2 signaling are established.
Abstract
The Mas-related G protein-coupled receptor X2 (MRGPRX2) mediates IgE-independent mast cell activation and is implicated in pseudoallergic drug reactions, chronic urticaria, atopic dermatitis, rosacea, neurogenic inflammation, and other mast cell-mediated disorders. Herein, we report the discovery of a pyrazolopyrimidine series as potent and orally bioavailable MRGPRX2 antagonists. A scaffold hybridization strategy, supported by systematic structure–activity relationship studies, yielded antagonists with nanomolar activity in both Gq/IP1 and beta-arrestin cellular assays. Addressing solubility limitations and CYP inhibition liability, while maintaining favorable pharmacokinetic properties, led to the identification of INCB187175 (compound 23), which exhibits good cellular potency and robust oral exposure across preclinical species. Importantly, functional activity was validated in a beta-hexosaminidase release assay using primary human mast cells, demonstrating potent inhibition of MRGPRX2-mediated degranulation. This activity translated in vivo, where INCB187175 effectively suppressed mast cell activation in an Evans blue extravasation assay. These findings establish the pyrazolopyrimidine chemotype as a promising scaffold for inhibition of MRGPRX2 signaling and support INCB187175 as a compelling drug candidate for further development in mast cell-mediated diseases.
Current data support MRGPRX2 as an investigational endotype-defining pathway rather than a universal driver of allergic or immune-mediated disease, and integrates these findings with receptor pharmacology and early clinical development.
W. Reinisch, Yi Li, Peng-Ju Xiong et al.· Clinical reviews in allergy...· 0 citations
A new non-CITCO chemotype for hCAR activation is established and YA8026 is identified as a promising lead compound for further development following the discovery of a structurally distinct class of hCAR activators based on the 2,4-diaminopyrimidine scaffold of ML241.
Yong Ai, Lin-Hao Li, Caitlin Lynch et al.· European journal of medicina...· 0 citations
S1PR1 is a clinically validated key therapeutic target for ulcerative colitis (UC), but approved S1PR1 agonists universally suffer from the core drawback of S1PR3-mediated cardiotoxicity. Herein, we designed and synthesized multiple novel arylethanone oxime ethers-based S1PR1 agonists. Among them, compound 13d exhibite...
Lan-Yan Ma, Yang Yang, Xiao Wang et al.· Journal of Medicinal Chemist...· 0 citations
This study identifies and characterize YL410, the first-in-class potent and selective GPR15 antagonist, providing new insights into the development of therapeutics for the treatment of obesity.
Aberrant activation of the NLRP3 (NACHT, LRR, and PYD domain-containing protein 3) inflammasome drives chronic diseases, necessitating robust therapeutic inhibitors. Despite the promise of phenol-based pyridazines, we sought to evaluate the possibility of replacing the phenol moiety. This article presents the medicin...
L. Bouché, S. Mesch, S. Steiner et al.· ACS Medicinal Chemistry Lett...· 0 citations
PKMYT1 mediates the inhibitory phosphorylation of CDK1 and represents a promising synthetic lethal target in p53-deficient or CCNE1-amplified malignancies. A series of PKMYT1 inhibitors featuring a novel monocyclic pyridine core structure was discovered, exhibiting improved selectivity and enhanced drug-like properties...